Icecure Medical Ltd. (ICCM)
NASDAQ:ICCM
Want to see ICCM full AI Analyst Report?
ICCM Stock Chart & Stats
$0.86
-$0.06(-4.41%)
At close: 4:00 PM EST
$0.86
-$0.06(-4.41%)
Day’s Range― - ―
52-Week Range$0.21 - $1.40
Previous CloseN/A
Volume318.06K
Average Volume (3M)637.69K
Market Cap
$15.04M
Enterprise Value$6.75M
Total Cash (Recent Filing)$8.12M
Total Debt (Recent Filing)$139.00K
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Aug 17, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding68,693,054
10 Day Avg. Volume755,395
30 Day Avg. Volume637,693
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.29
Price to Sales (P/S)11.48
P/FCF Ratio-2.66
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue1.89
Enterprise Value/Gross Profit5.18
Enterprise Value/Ebitda-0.44
Forecast
1Y Price Target
$1.00Price Target Upside16.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.2
Revenue Forecast (FY)$6.37M
Bulls Say, Bears Say
Bulls Say
Regulatory Clearance & Professional EndorsementFDA marketing authorization plus the American Society of Breast Surgeons’ guidance provide durable regulatory and professional validation. This lowers adoption barriers, bolsters clinician confidence, and supports broader hospital procurement and sustained procedure volumes that drive repeat consumable sales over time.
Robust Long‑term Clinical Outcomes (ICESECRET 5‑year)Multi‑year positive outcomes give enduring clinical credibility across oncologic indications. Strong long‑term efficacy reduces physician reluctance, supports guideline inclusion and payer conversations, and underpins a sustainable installed base that drives recurring probe and consumable demand.
Low Leverage And Positive EquityMinimal debt and a positive equity base reduce near‑term solvency risk and provide financing optionality. This capital structure gives management flexibility to pursue staged commercial expansion and complete post‑market studies without immediate default risk, improving resilience during the multi‑quarter commercialization ramp.
Bears Say
High Cash Burn And Weak Cash GenerationSustained negative operating and free cash flow at this magnitude creates runway pressure and forces reliance on external funding. That elevates dilution risk, can constrain hiring and commercial investments, and may slow the funded execution of studies and reimbursement efforts needed for durable revenue growth.
Profitability Far From ScalableVery large losses relative to a small revenue base imply a cost structure not yet scalable. Moderate gross margins are overwhelmed by R&D and G&A, meaning substantial and sustained revenue expansion is required to approach break‑even; otherwise continued equity erosion and funding needs persist.
Reimbursement Timing And UncertaintyKey physician CPT‑1 and pass‑through outcomes are multi‑year and uncertain, limiting clear payment pathways. Prolonged reimbursement ambiguity reduces hospitals’ and physicians’ willingness to invest in capital systems, slowing conversions and creating structural headwinds for predictable, durable revenue growth.
Icecure Medical News
ICCM FAQ
What was Icecure Medical Ltd.’s price range in the past 12 months?
Icecure Medical Ltd. lowest stock price was $0.21 and its highest was $1.40 in the past 12 months.
What is Icecure Medical Ltd.’s market cap?
Icecure Medical Ltd.’s market cap is $15.04M.
When is Icecure Medical Ltd.’s upcoming earnings report date?
Icecure Medical Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 77 days.
How were Icecure Medical Ltd.’s earnings last quarter?
Icecure Medical Ltd. released its earnings results on May 12, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.047 by -$0.013.
Is Icecure Medical Ltd. overvalued?
According to Wall Street analysts Icecure Medical Ltd.’s price is currently Undervalued.
Does Icecure Medical Ltd. pay dividends?
Icecure Medical Ltd. does not currently pay dividends.
What is Icecure Medical Ltd.’s EPS estimate?
Icecure Medical Ltd.’s EPS estimate is -0.05.
How many shares outstanding does Icecure Medical Ltd. have?
Icecure Medical Ltd. has 68,693,054 shares outstanding.
What happened to Icecure Medical Ltd.’s price movement after its last earnings report?
Icecure Medical Ltd. reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.047. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Icecure Medical Ltd.?
Currently, no hedge funds are holding shares in ICCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Icecure Medical Ltd.
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
ICCM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys strong positive momentum driven by 26% revenue growth, outsized North America (84%) and U.S. (31%) gains, FDA clearance, increasing active accounts (+46%), an approved 30‑site Choice post‑market study, and expanding commercial and clinical validation. Key near‑term risks include reimbursement timing (CPT‑1 and pass‑through uncertainty), limitations for office‑based reimbursement, and multi‑quarter conversion timelines for leads to system sales. On balance, the positives (regulatory milestone, accelerating sales, study approval and pipeline growth) outweigh the challenges, while some execution and reimbursement risks remain.View all ICCM earnings summariesICCM Stock 12 Month Forecast
Average Price Target
$1.00
▲(16.28% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.06% Mutual Funds
4.14% Other Institutional Investors
95.80% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---